


AMENDMENT TO THE CLAIMS

A listing of the claims presented in this patent application appears below. This listing replaces all prior versions and listings of claims in this patent application.

1. (Currently amended) A composition for treatment of inflammation comprising (1) a compound selected from the group consisting of reduced isoolpha acids, tetra-hydroisoalpah acids, and hexa-hydroisoalpah acids; and (2) a reduced isoolpha acid (RIAA) and methylxanthine, wherein the compound RIAA and the methylxanthine are in anti-inflammatory synergistic amounts having a ratio of 100:1 to 1:100 and wherein said composition comprises from 0.5 to 10000 mg of said compound RIAA.
2. (Currently Amended) The composition of claim 1, wherein the RIAA compound selected from the group consisting of reduced isoolpha acids, tetra-hydroisoalpah acids, and hexa-hydroisoalpah acids is derived from hops.
3. (Cancelled)
4. (Currently Amended) The composition of claim 1, wherein said RIAA is compound selected from the group consisting of reduced isoolpha acids, tetra-hydroisoalpah acids, and hexa-hydroisoalpah acids comprises a member of Genus A having the formula:



wherein R' is selected from the group consisting of carbonyl, hydroxyl, OR, and OCOR, wherein R is alkyl;

and wherein R'' is selected from the group consisting of CH(CH₃)₂, CH₂CH(CH₃)₂, and CH(CH₃)CH₂CH₃.

5. (Cancelled)

6. (Currently Amended) The composition of claim 1, wherein said RIAA is compound selected from the group consisting of reduced isoalpha acids, tetra-hydroisoalpha acids, and hexa-hydroisoalpha acids comprises a member selected from the group consisting of dihydro-isohumulone, dihydro-isocohumulone, dihydro-adhumulone, ~~tetrahydro-isohumulone, tetrahydro-isocohumulone, tetrahydro-adhumulone, hexahydro-isohumulone, hexahydro-isocohumulone, and hexahydro-adhumulone.~~

7. (Original) The composition of claim 1, wherein said methylxanthine is selected from caffeine; theobromine; theophylline; aminophylline; doxofylline; pentoxifylline; 8-oxopentoxifylline; 8-oxolisofylline; lisofylline; 1-proparagyl 3,7-dimethyl xanthine; 7-proparagyl 1,3-dimethyl xanthine; 3-proparagyl 1,7-dimethyl xanthine; 1,3,7-triproparagyl xanthine; 3-isobutyl-1-methylxanthine (IBMX); 1,3,7-tripropyl xanthine; 7-benzyl-IBMX; 1-propyl 3,7-dimethyl xanthine; 1,3-dipropyl 7-methyl xanthine; 1,3-dipropyl 7-proparagyl xanthine; 3,7-dimethyl 1-propyl xanthine; and 7-allyl 1,3-dimethyl xanthine.

8. (Canceled)

9. (Previously presented) The composition of claim 8, wherein the methylxanthine is caffeine.

10. (Canceled)

11. (Previously presented) The composition of claim 10, wherein the composition comprises about 50 to 7500 mg of the RIAA compound selected from the group consisting of reduced isoalpha acids, tetra-hydroisoalpha acids, and hexa-hydroisoalpha acids.

12. (Previously presented) The composition of claim 1, wherein the composition comprises about 0.001 to 10 weight percent of the RIAA compound selected from the group consisting of reduced isoalpha acids, tetra-hydroisoalpha acids, and hexa-hydroisoalpha acids.

13. (Previously presented) The composition of claim 12, wherein the composition comprises about 0.1 to 1 weight percent of the RIAA compound selected from the group consisting of reduced isoalpha acids, tetra hydroisoalpha acids, and hexa hydroisoalpha acids.

14. (ORIGINAL) The composition of claim 1, wherein the composition further comprises a pharmaceutically acceptable carrier.

15. (ORIGINAL) The composition of claim 1, wherein the composition is formulated for administration orally, topically, parenterally, or rectally.

16-32. (Cancelled)